blu-451
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 4, 2022 (NCT05241873)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Antineoplastic Agents · Phase 1/Phase 2
- Brain Neoplasms · Phase 1/Phase 2
- Bronchial Neoplasms · Phase 1/Phase 2
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Bronchogenic · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Genes, erbB-1 · Phase 1/Phase 2
- Lung Diseases · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Mutation · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neoplasms by Histologic Type · Phase 1/Phase 2
- Neoplasms by Site · Phase 1/Phase 2
- Respiratory Tract Diseases · Phase 1/Phase 2
- Respiratory Tract Neoplasms · Phase 1/Phase 2
Mechanism of action
- Epidermal growth factor receptor erbB1ANTAGONIST
EGFR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05241873 | Phase 1/Phase 2 (Phase 2) | Mar 4, 2022 | Blueprint Medicines Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blueprint Medicines Corporation | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1